Centro Hospitalar Universitario Lisboa Central E.P.E.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Research at the site explores innovative approaches to prevent recurrent cerebrovascular events. A study evaluates whether Milvexian can lower the risk of Acute Ischemic Stroke and high‑risk transient ischemic attacks.
- Milvexian efficacy in stroke prevention
- Safety profile after acute ischemic events
Centro Hospitalar Universitario Lisboa Central is advancing cardiovascular care through these trials.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
A rare genetic skin condition, Netherton syndrome, is being investigated to determine if the antibody spesolimab improves disease control.
- Spesolimab response in Netherton syndrome
- Assessment of safety in hereditary dermatologic disorder
The Neurology Department supports this research at Centro Hospitalar Universitario Lisboa Central.
Eye Diseases
Patients with vision loss from macular edema secondary to retinal vein occlusion are receiving a higher dose of the anti‑VEGF agent aflibercept to assess visual improvement and safety.
- Aflibercept dosing comparison for macular edema
- Best‑corrected visual acuity outcomes
This ophthalmic investigation is conducted at Centro Hospitalar Universitario Lisboa Central.
Immune System Diseases
The department evaluates novel biologics for severe allergic skin disorders. Trials test rocatinlimab in adolescents with moderate‑to‑severe atopic dermatitis and tralokinumab for atopic hand eczema.
- Rocatinlimab safety in adolescent atopic dermatitis
- Tralokinumab efficacy in hand eczema
These immune‑targeted studies are part of the research portfolio at Centro Hospitalar Universitario Lisboa Central.
Nervous System Diseases
Long‑term safety of the oral agent tolebrutinib is being monitored in adults with relapsing and progressive multiple sclerosis, aiming to expand therapeutic options for this chronic condition.
- Tolebrutinib tolerability in multiple sclerosis
- Impact on disease progression
The Neurology team at Centro Hospitalar Universitario Lisboa Central leads this multiple sclerosis research.
Respiratory Tract Diseases
A pediatric study adds selexipag to standard therapy for children with Pulmonary Arterial Hypertension, seeking to delay disease progression and improve outcomes.
- Selexipag as add‑on in pediatric PAH
- Comparison with placebo in disease delay
This respiratory investigation is coordinated through Centro Hospitalar Universitario Lisboa Central.
Skin and Connective Tissue Diseases
Multiple trials target atopic skin inflammation, including a phase 3b study of tralokinumab for moderate‑to‑severe atopic hand eczema and a safety assessment of rocatinlimab in adolescent atopic dermatitis.
- Tralokinumab for hand eczema severity
- Rocatinlimab tolerability in adolescents
These skin‑focused studies are conducted at Centro Hospitalar Universitario Lisboa Central.
Virus Diseases
An European randomized trial evaluates a therapeutic approach for confirmed Monkeypox infection, measuring time to resolution of cutaneous and mucosal lesions.
- Efficacy against monkeypox lesions
- Safety compared with control group
The virology component of this research is hosted by Centro Hospitalar Universitario Lisboa Central.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 13 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Insel Gruppe AG1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Insel Gruppe AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Hospitalar Universitario Lisboa Central E.P.E.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tenecteplase | 2 | Unknown | 2025-01-23 | 2025-08-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.